



## Purpose

HOSPITAL+ HEALTH CENTRE

To provide guidelines for the administration of Albumin using the syringe method in the Neonatal Intensive Care Unit.

#### Site Applicability

Neonatal Intensive Care Unit.

#### Equipment

- Patient chart with prescriber order and consent for blood transfusion
- Personal Protective Equipment (PPE): gloves, goggles, +/-gown, mask
- Chlorhexidine/alcohol swabs
- Infusion pump "brain"
- Smartsite Cap (for post transfusion CVC cap change)
- 60 mL syringe for albumin
- 18 gauge needle for aspirating albumin
- 10 mL syringe with 0.9% Normal Saline for priming & flushing the line
- Sterile green towel
- Needleless connector (cap)
- Microbore 60" tubing

From Transfusion Medicine Laboratory (TML)

- Bottle of Albumin
- Transfusion tag attached to bottle of Albumin
- Transfusion record

PRE-TRANSFUSION			
PROCEDURE		Rationale	
1. ENSURE order for blood product exists. For neo-		Blood products shall be prescribed by a health	
natal dosage guidelines, see table 1 below.		care provider with blood prescribing privileges.	
	Table 1: NICU Alb		
Albumin percentage	Gram per mL	Dose	
5% Albumin	1 gram = 20 mL	10 to 20 mL/kg/dose	
25% Albumin	1 gram = 4 mL	2 to 4 mL/kg/dose	
<ul> <li>2. CONFIRM that informed consent for blood transfusion is complete and current.</li> <li>Informed consent need not be obtained:</li> <li>When urgent treatment is necessary to preserve a patient's life and continuing health, and</li> <li>When it is not reasonably possible to obtain consent, and</li> <li>When there is no substitute decision maker</li> </ul>		Informed Consent is required by law for the transfusion of all albumin products.	
3. <b>ENSURE</b> that the guardian is aware of the planned transfusion. <b>Explain</b> the reason for transfusion and transfusion procedure to guardian. <b>Provide</b> guardian with the information pamphlet "Blood Transfusion Answers to Some Common Questions" if necessary.		Allow the guardian to prepare for the procedure. To ensure that the guardian understands the reason for transfusion and the transfusion procedure.	



## DOCUMENT TYPE: PROCEDURE

4. <b>PREPARE</b> the Blood Component/Derivative/Factor Concentrate Request Form and the Blood Release Request Form.		To avoid unnecess	ary delay in transfusion.
	<b>Give</b> both forms to the unit clerk and ask the unit		
	clerk to <b>send</b> the Blood Component/Derivative/		
	Factor Concentrate Request Form to TML.		
	The Blood Release Request Form is not sent to	This form is takon h	by the porter to TML when the
_	TML at this point.	blood product is rea	ady for pick up.
5. 🛆	No identification band, No Transfusion	sure that a patient identification band is in placeA missing identification band is a significationidentification band, No Transfusionin patient misidentification and wrong proceedingpatient incidents.Transfusion should not be administered to patients who lack positive identification.	
6.	<b>ENSURE</b> peripheral vascular access (PIV), central	Gauge or lumen size should be large enough to	
0.	vascular access line (CVC) or umbilical venous		n the specified administration
	catheter (UVC) of sufficient gauge is established for	time.	
	the transfusion of blood product(s) based on clinical		
	status of patient and urgency of transfusion, see		
	table 2 below.		
Та	ble 2: Intravenous Access for Administration of Blo	od Products	
Int	ravenous Access	Lumen Size	Transfusion
PI	/	≥ 26 Gauge	
U٧	/C	≥ 3.5 French	Can be used for transfusion
Cu	ffed & uncuffed Central Venous Catheter	≥ 3 French	of all blood products.
Cu	ffed & uncuffed Peripherally Inserted Central Catheter	≥ 3 French	•
		< 2.6 French	May use " <b>red" lumen</b> for
Cu	ffed & uncuffed Peripherally Inserted Central Catheter	double lumen	transfusion of all blood
			products.
7.	<b>ENSURE</b> a dedicated line for the administration of	To avoid inadverter	nt co-administration of
	albumin.	incompatible fluids	or medications
	• Albumin is compatible with 0.9% Normal Saline		
	and D5W.		
8.	<b>PERFORM</b> a pre transfusion patient assessment	Identify any clinical	manifestations that may be
	within 30 minutes of commencing the transfusion		the transfusion e.g. fever.
	and <b>document</b> findings.	, ,	sting clinical manifestations
	Measure:	5 51	ed with a transfusion reaction
1	Heart rate	e.g. fever or pre-ex	
	Blood pressure		g clinical manifestations that
	Temperature		e patient to a transfusion
	<ul> <li>Respiratory rate &amp; O<sub>2</sub> Saturation level</li> </ul>	•••••	fusion Associated Circulatory
Inc	lude:	Overload.	· · · · · · · · · · · · · · · · · · ·
Chest auscultation			levels so that any transfusion-
		related deviations in patient's clinical condition will	
A check for positive fluid balance		be recognized	
9.	When TML phone to state that the blood product is	Ensure that the per	son transporting the blood
	ready for pick up the unit clerk will inform the RN.	-	right blood product for the
	The RN will instruct the unit clerk to:	right patient.	
	• Send the porter for the blood product, or		
	• Wait until the RN is ready to proceed with the		
	transfusion.		
	The unit clerk will <b>give</b> the porter the Blood Release		
	Request Form to take to TML.		

C-06-12-61167

Published Date: 19-Apr-2021 Review Date: 19-Apr-2024

Page 2 of 8 This is a controlled document for BCCH& BCW internal use only – see Disclaimer at the end of the document. Refer to online version as the print copy may not be current.



# BC WOMEN'S HOSPITAL+ HEALTH CENTRE

## DOCUMENT TYPE: PROCEDURE

<ul> <li>NOTE: START the transfusion promptly.</li> <li>Consult TML if there are concerns about completing the transfusion within the four hour time limit.</li> <li>If the transfusion cannot be started return the blood product to TML promptly.</li> <li>10. PERFORM the pre transfusion check with second RN.</li> </ul>	<ul> <li>Albumin is stored at room temperature.</li> <li>To avoid unnecessary wastage</li> <li>To ensure that the Right Patient receives the Right Product.</li> </ul>
<ul> <li>a. Visual Inspection. The integrity of the albumin product is checked for:</li> <li>Turbidity Particulate matter</li> <li>Abnormal colour Tampered cap</li> <li>Albumin that appears abnormal should not be transfused without further investigation. Contact TML @ 7388 for an explanation of abnormal appearance.</li> </ul>	To detect any abnormalities that may indicate that the transfusion should not proceed.
<ul> <li>b. CONFIRM that Informed Consent has been obtained.</li> <li>c. Check that the patient details on all documentation match:</li> <li>First and last name</li> </ul>	
<ul> <li>DOB</li> <li>MRUN <ul> <li>on</li> </ul> </li> <li>Admission summary in the patient chart</li> <li>Physicians order</li> <li>Product Tag</li> </ul>	Consent is required for the transfusion of albumin. The intended patient must be properly identified
<ul> <li>Transfusion record</li> <li><b>d.</b> Check the physician order for: <ul> <li>Albumin concentration</li> <li>Volume in mLs</li> <li>Date on the order form</li> <li>Rate or duration of infusion</li> </ul> </li> </ul>	prior to transfusion.
<ul> <li>Intra/post transfusion medication orders</li> <li>Note:</li> <li>Administration of 25% albumin in error, instead of 5% albumin, could result in circulatory overload.</li> </ul>	To ensure that you are aware of the infusion rate, pre or post medication etc. that has been ordered for the transfusion.
<ul> <li>e. Compare details and match information on the Albumin label, the product tag &amp; transfusion record for the following:</li> <li>Patient information:</li> <li>✓ First &amp; last name</li> <li>✓ DOB</li> <li>✓ MRUN</li> <li>Product information:</li> <li>✓ Concentration of albumin</li> <li>✓ Lot number</li> <li>✓ Expiry date &amp; time</li> </ul>	

C-06-12-61167



## DOCUMENT TYPE: PROCEDURE

W

BC WOMEN'S HOSPITAL+ HEALTH CENTRE

f.	<ul> <li>Check for any TML comments.</li> <li>Final check in the presence of the patient         <ol> <li>Ask parent/guardian, where possible, to state their infant's full name and date of birth and compare to patient details on patient identification band.</li> </ol> </li> <li>Compare the patient details:         <ol> <li>First and last name</li> <li>DOB</li> <li>MRUN</li> </ol> </li> <li>With patient details on:         <ul> <li>Patient identification band</li> <li>Product Tag</li> <li>Transfusion Record</li> <li>If you find any discrepancies in the patient identifiers DO NOT proceed. Contact TML @             <ol> <li>7388 immediately</li> <li>The product tag must remain attached to the</li> </ol> </li> </ul></li></ul>	The majority of transfusion-associated mortality is due to patients receiving the wrong product, or blood intended for another patient. The bedside check is a vital step in preventing serious transfusion error. Vigilance in checking to ensure that the right product is given to the right patient is mandatory. If this product is not the intended product for your patient another patient may be at risk i.e. another patient may be about to receive the wrong product.
	product for the duration of the transfusion.	
<ul> <li>11. DOCUMENT the checking procedure by signing the transfusion record.</li> <li>Record: <ul> <li>Signature of both staff members who carried out the pre transfusion check</li> <li>Date of transfusion</li> <li>Start time.</li> </ul> </li> </ul>		To confirm that the pre transfusion checking procedure has been completed.

white cap



## ADMINISTRATION OF ALBUMIN: SYRINGE METHOD: NICU

## DOCUMENT TYPE: PROCEDURE

TRANSFUSION			
PROCEDURE	Rationale		
<ul> <li>12. Immediately after the verification checks have been completed INITIATE the transfusion:</li> <li>Wash hands; apply personal protective equipment and prepare field and equipment.</li> </ul>	To prevent microbial contamination of product.		
<ul> <li>Flip off plastic cap on top of the bottle and expose rubber stopper.</li> <li>Clean the exposed rubber stopper with alcohol swab.</li> <li>Attach filter needle, if supplied by manufacturer, to a sterile disposable plastic syringe.</li> </ul>	The product tag must remain attached to the blood product for the duration of the procedure.		
<ul> <li>Insert needle into the area delineated by the raised ring in the center of rubber stopper. The stopper should be penetrated perpendicular to the plane of the stopper within the ring. The bottle should be on a flat surface.</li> <li>Aspirate the required volume of albumin from the bottle</li> </ul>	To prevent the entry/growth of microorganisms as albumin contains no preservative.		
into the syringe. <b>Include</b> additional volume to allow for	CVC or PICC line		
discard in the microbore tubing.	Image 1		
<ul> <li>Remove and discard the needle from the syringe.</li> <li>Attach the microbore tubing to the syringe.</li> <li>Remove product tag from albumin bottle and attach to albumin syringe.</li> <li>Prime the microbore tubing with albumin.</li> <li>Load syringe into syringe pump and prime using prime option on pump. Label pump channel.</li> <li>Program pump to run at prescribed infusion rate, see infusion rate table 3 below.</li> <li>Double-check the programmed rate and volume to be infused.</li> <li>Monot re-enter the albumin bottle once required volume of albumin has been aspirated into syringe.</li> </ul>	Sterile white cap		
<ul> <li>Clamp CVC or PICC. Delay existing infusion for the duration of the transfusion.</li> <li>Clean connection with CHG/ALC swab, detach and cap existing infusion from CVC or PICC using a sterile white cap.</li> <li>Set aside in sterile green towel for post transfusion reconnection.</li> </ul>			
<ul> <li>Clean cap with CHG/ALC swab CVC cap and flush with 1mL of 0.9% Normal Saline using push-pause action and clamp.</li> <li>Connect blood product line directly onto cap and start</li> </ul>			
<ul> <li>transfusion.</li> <li>If dedicated access is PIV:</li> <li>Clean connection with CHG/ALC swab</li> <li>Convert PIV to saline lock.</li> <li>Connect blood product line to patient's IV access and start transfusion</li> </ul>	The product tag must remain attached to the product for the duration of the transfusion		



Table 3: NICU Albumin Infusion Rates			
Albumin percentage	Gram per mL Infusion Rates		
5% Albumin	1 gram = 20 mL	Over 30 minutes to 2 h	
25% Albumin	1 gram = 4 mL	The maximum infusion rate is 1.5 mL/kg/h	
13. MONITORING see table	e 4 below:		
Table 4: Patient Monitorir	ng during Blood Produ	ct Transfusion	
of each unit (when product transfusion reaction.	actually reaches the pat	<b>e</b> , the patient for the <b>first 15 minutes</b> following the start tient) and observe for signs and symptoms of a <i>occurs, symptoms usually appear early in the</i>	
Measure Vital signs:		Vital signs include:	
<ul> <li>15 minutes after the start</li> </ul>	t of the transfusion	Heart rate	
<ul> <li>30 minutes after the start</li> </ul>		Blood Pressure	
<ul> <li>60 minutes after the start</li> </ul>		▲ Temperature	
<ul> <li>Hourly for remainder of the</li> </ul>		Respiration Rate	
<ul> <li>Within 60 minutes of con</li> </ul>			
<ul> <li>infant probe can be tren</li> <li>▲ Axilla temperatures must transfusion reaction.</li> <li>14. If a second bottle of albut the function of albut the second bottle of albut the second bott</li></ul>	<ul> <li>that the pre-transfusion patient assessments 1 and 2 were measured by axilla thermometer and the infant probe can be trended.</li> <li>▲ Axilla temperatures must be obtained whenever there is an atypical reading e.g. suspect possible transfusion reaction.</li> <li>14. If a second bottle of albumin is required:</li> </ul>		
<ul> <li>Repeat steps 10 to</li> <li>Flush intravenous</li> </ul>	access with 1 to 2 mL of in between transfusion.	ed next bottle of albumin.	
15. In the event of a suspect		To minimize patient harm.	
STOP the transfusion		To keep the vein open.	
<ul> <li>Disconnect transfusion tubing from cap.</li> <li>Flush catheter with 1 to 2 mL 0.9% Normal</li> </ul>		To seek direction for patient management.	
• Flush cameter with 1 to 2 mL 0.9% Normal Saline.		To ensure correct procedure is followed.	
Start 0.9% Normal Saline		To report the transfusion reaction.	
Reassess patient vital signs			
<ul> <li>Reconfirm unique identifiers on both patient and blood product.</li> </ul>		t	
Seek assistance and	d <b>notify</b> physician.		
	Reaction Procedure &		
	on Reaction Report For	m.	
16. COMPLETION of transfusion.		Volume issued in the syringe allows for some	
<b>STOP</b> the infusion when the prescribed volume is		is discard in the microbore tubing.	
infused.			
If the dedicated access			
	n between microbore		
tubing IV access.	robore tubing and ouring		
Disconnect the mic	robore tubing and syring	je	

C-06-12-61167

BC WOMEN'S HOSPITAL+ HEALTH CENTRE



## **DOCUMENT TYPE: PROCEDURE**

<ul> <li>line.</li> <li>Flush the catheter with 1 mL of 0.9% Normal Saline using pre filled syringe and clamp.</li> <li>Change cap.</li> <li>Reconnect and start previously set aside existing infusion(s).</li> <li>If dedicated access is PIV:</li> <li>Clean the connection between microbore tubing IV access.</li> <li>Flush the catheter with 1 mL of 0.9% Normal Saline using pre filled syringe and clamp.</li> <li>Convert saline lock to PIV and start existing infusion(s).</li> </ul>	To ensure all the product is cleared from the connrction
infusion(s).	
17. <b>DISCARD</b> syringe and microbore tubing in	Universal precautions.
biohazard container	
18. DOCUMENT	At the time of the transfusion the patient's medical
Complete the transfusion record:	chart shall be updated
Volume infused	,
End time	
Transfusion reaction noted: yes or no	
Complete the product tag:	
<ul> <li>Date/Time transfused</li> </ul>	
Transfused by	
<ul> <li>Transfusion reaction noted: yes or no</li> </ul>	
Complete patient notification tag section:	
<ul> <li>Date of transfusion</li> </ul>	
Record in patients chart:	
Vital signs	
Volume infused	
<ul> <li>Patient's response to transfusion</li> </ul>	
<ul> <li>All interventions related to transfusion</li> </ul>	
<ul> <li>If a transfusion reaction occurred record all</li> </ul>	
signs and symptoms experienced by the	
patient	
19. <b>FILE</b> transfusion record in patient's chart.	To any use full trace bility of the product
	To ensure full traceability of the product.
20. <b>GIVE</b> guardian the patient notification tag. The	All patients who receive a blood product should
notification tag may be filed in the patient's chart	receive notification of the transfusion in writing.
and given to the guardian at discharge.	5
21. <b>RETURN</b> the completed product tag to TML	To ensure full traceability of the product.
22. <b>OBSERVE</b> for signs & symptoms of a transfusion	Transfusion reactions can occur after the
reaction post transfusion.	completion of the transfusion.
	<u> </u>

## References

American Association of Blood Banks. (2010). Primer of blood administration. Bethesda, MD.

BC Provincial Blood Coordinating Office. (2007). Transfusion medicine medical policy manual. Vancouver, BC.

British Committee for Standards in Haematology. (2009). *Guideline on the administration of blood components*). London.

Callum, JL. (2011). bloody easy 3. Toronto, ON. Ontario Regional Blood Coordinating Network.

## ADMINISTRATION OF ALBUMIN: SYRINGE METHOD: NICU

DOCUMENT TYPE: PROCEDURE

Lima, A. (2010). *bloody easy blood administration*. Toronto, ON. Ontario Regional Blood Coordinating Network. Canadian Standards Association. (2010). CAN/CSA Z902-10 A national standard of Canada – blood and

blood components. Mississauga, ON.

McClelland, D.B.L. (2007). *Handbook of transfusion medicine (4<sup>th</sup> ed)*. Edinburgh. United Kingdom Blood Services.

Plasbumin 5% product monograph.

Alburex product monograph.

HOSPITAL+ HEALTH CENTRE

Albumin 25% product monograph.

#### **Developed By**

C&W Transfusion Safety – Transfusion safety Nurse Clinician

#### Version History

DATE	DOCUMENT NUMBER and TITLE	ACTION TAKEN
06-Apr-2021	C-06-12-61167 Administration Of Albumin: Syringe	Approved at: Transfusion Safety Committee
	Method: NICU	

## Disclaimer

This document is intended for use within BC Children's and BC Women's Hospitals only. Any other use or reliance is at your sole risk. The content does not constitute and is not in substitution of professional medical advice. Provincial Health Services Authority (PHSA) assumes no liability arising from use or reliance on this document. This document is protected by copyright and may only be reprinted in whole or in part with the prior written approval of PHSA.